MDElliottMD: Create Lixisenatide stub: short-acting GLP-1 receptor agonist (Adlyxin / Lyxumia, FDA 2016, withdrawn from US market 2023). Closes last redlink in Category:GLP-1 receptor agonists.

2026-05-19T03:16:02Z

Create Lixisenatide stub: short-acting GLP-1 receptor agonist (Adlyxin / Lyxumia, FDA 2016, withdrawn from US market 2023). Closes last redlink in Category:GLP-1 receptor agonists.

New page

{{Stub}}
{{MedTemplate
| generic = Lixisenatide
| classes = GLP-1 receptor agonist
| intro = Lixisenatide is a short-acting once-daily injectable [[:Category:GLP-1 receptor agonists|GLP-1 receptor agonist]] approved for type 2 diabetes mellitus. It was approved by the FDA in July 2016 under the brand name '''Adlyxin''' (and as '''Lyxumia''' in the European Union), and was withdrawn from the United States market in 2023 by its manufacturer Sanofi, citing insufficient demand; it remains available in other markets. Pharmacologically it is most similar to [[Exenatide|exenatide]], with which it shares the short-acting prandial-glucose-suppressing profile, in contrast with the long-acting once-weekly [[Semaglutide|semaglutide]] and [[Dulaglutide|dulaglutide]].
}}

[[Category:GLP-1 receptor agonists]]

Lixisenatide - Revision history

MDElliottMD: Create Lixisenatide stub: short-acting GLP-1 receptor agonist (Adlyxin / Lyxumia, FDA 2016, withdrawn from US market 2023). Closes last redlink in Category:GLP-1 receptor agonists.